G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort

A. Coilly , C. Fougerou (1) , V. de Ledinghen , P. Houssel-Debry , C. Duvoux , V. Di Martino , S. Radenne , Nassim Kamar (2, 3) , L. D’alteroche , V. Leroy , V. Canva , P. Lebray , C. Moreno , J. Dumortier (4) , C. Silvain , C. Besch , P. Perré , D. Botta-Fridlund , R. Anty , A. Rohel , A. Renault (5) , H. Danjou , J. -C. Duclos-Vallee , G. -P Pageaux

1 Service de Pharmacologie [Rennes]
2 I2MR - Institut de médecine moléculaire de Rangueil
3 Département de Néphrologie et Transplantation d'organes [CHU Toulouse]
4 Département d'hépatologie
5 CIC - Centre d'Investigation Clinique [Rennes]

no abstract

Domaines: Sciences du Vivant [q-bio]

A. Coilly, C. Fougerou, V. de Ledinghen, P. Houssel-Debry, C. Duvoux, et al.. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort. The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. pp.S236--S237, ⟨10.1016/S0168-8278(15)30103-3⟩. ⟨hal-01162709⟩